|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||323.49|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hutchison China MediTech Limited announced that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and theliatinib, were presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology , held in Xiamen, China, from September 26 to 30, 2017.
Hutchison China MediTech Limited has initiated a Phase I clinical trial of HMPL-689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting phosphoinositide-3 kinase delta isoform , a key component in the B-cell receptor signaling pathway.
Hutchison China MediTech Limited today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Committee with effect from March 27, 2017.
Hutchison China MediTech Limited today announces that it has initiated the first-in-human Phase I clinical trial of HMPL-453 in Australia. HMPL-453 is a novel, highly selective and potent small molecule inhibitor targeting fibroblast growth factor receptor .
Hutchison China MediTech Limited today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of the Audit Committee, Remuneration Committee and Technical Committee of Chi-Med; and Mr Shigeru Endo tendered his resignation as Non-executive Director and Mr Christopher Nash tendered his resignation as Senior Independent ...
Hutchison China MediTech Limited today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients with advanced or metastatic non-small cell lung cancer in China.
Hutchison China MediTech Limited today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase inhibitor, HMPL-523, in patients with hematological malignancies in China.